1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
660ECECD0AE56C6D985256F1E0052B570
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/developing-the-high-performance-medical-affairs-function-study-excerpt?OpenDocument
18
19OpenDocument
2052.23.234.7
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25RC




Products & Services

Developing the High-Performance Medical Affairs Function: Study Excerpt

ID: WP-17


Pages: 7


Published: Pre-2014


Delivery Format: Online


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Download White Paper

 

  • STUDY OVERVIEW
  • BENCHMARK CLASS
In today's challenging healthcare environment, medical affairs' role has become even more crucial to pharmaceutical companies' success. Confronted with declining R&D productivity, escalating development costs, increasing competition, growing price pressures, and intensified regulatory and public scrutiny, pharmaceutical companies seek to maintain double-digit revenue and earnings growth demanded by investors. This white paper highlights findings from a larger research effort undertaken by Best Practices, LLC to benchmark the organization and structure of medical affairs departments at top pharmaceutical companies.

Industries Profiled:
Pharmaceutical; Medical Device; Biotech; Health Care


Companies Profiled:
Abbott Laboratories; Roche; Amgen; AstraZeneca; Eli Lilly; Merck